Literature DB >> 2573414

Amplification of protooncogenes in surgical specimens of human lung carcinomas.

M Shiraishi1, M Noguchi, Y Shimosato, T Sekiya.   

Abstract

The possible existence of amplification or rearrangement of protooncogenes was examined in more than 100 surgical specimens of human lung carcinoma. Protooncogenes were amplified in 28% of the carcinomas. About 90% of the amplified genes were of the myc, ras, or erbB family. Of the myc family genes, myc was amplified in 14 of 137 tumors and L-myc in four of 108 tumors, but N-myc was not amplified. A high frequency of amplification of myc was observed in squamous cell carcinomas (seven of 37) and of L-myc in small cell carcinomas (two of six). Of the ras family genes, K-ras-2 was amplified in six of the 137 tumors and N-ras in two of the 137 tumors, but no amplification of H-ras-1 was detected. Seven of the eight cases of amplified ras genes were in advanced pathological stages. Of the erbB family genes, erbB-1 (epidermal growth factor receptor) was amplified in 10 of 114 tumors and erbB-2 (HER-2/neu) in one of 51 tumors. Amplifications of the myc, ras, and erbB family genes might be one of the crucial DNA abnormalities involved in the development of human lung carcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573414

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Intrachromosomal rearrangements fusing L-myc and rlf in small-cell lung cancer.

Authors:  T P Mäkelä; J Kere; R Winqvist; K Alitalo
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

2.  G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity.

Authors:  L F Allen; R J Lefkowitz; M G Caron; S Cotecchia
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  AIS is an oncogene amplified in squamous cell carcinoma.

Authors:  K Hibi; B Trink; M Patturajan; W H Westra; O L Caballero; D E Hill; E A Ratovitski; J Jen; D Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 4.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

5.  Preferential isolation of DNA fragments associated with CpG islands.

Authors:  M Shiraishi; L S Lerman; T Sekiya
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  Detection of a common mutation of the catalase gene in Japanese acatalasemic patients.

Authors:  Y Kishimoto; Y Murakami; K Hayashi; S Takahara; T Sugimura; T Sekiya
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

7.  Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.

Authors:  Zhen Zhao; Rui Li; Sha Sha; Qiong Wang; Weidong Mao; Tao Liu
Journal:  Cancer Biol Ther       Date:  2014-07-21       Impact factor: 4.742

8.  Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells.

Authors:  Kazutoshi Komiya; Naoko Sueoka-Aragane; Akemi Sato; Takashi Hisatomi; Toru Sakuragi; Masahiro Mitsuoka; Toshimi Sato; Shinichiro Hayashi; Hiroto Izumi; Makoto Tsuneoka; Eisaburo Sueoka
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

9.  MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.

Authors:  Federico Cappuzzo; Marileila Varella-Garcia; Elisa Rossi; Sujatha Gajapathy; Marialuisa Valente; Harry Drabkin; Robert Gemmill
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

10.  MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study.

Authors:  Rita de Cássia S Alves; Rosalva Thereza Meurer; Adriana Vial Roehe
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.